医院获得性肺炎中药干预治疗对照试验的疗效评价

目的:评价中药干预治疗医院获得性肺炎的疗效和安全性。方法:收集中药干预治疗医院获得性肺炎随机对照试验文献,纳入的文献按不同的治疗策略进行分层,采用Jadad计分表评价纳入文献的质量,对纳入的试验作系统评价。结果:符合纳入标准的论文8篇,涉及患者557例,经Meta分析结果表明:中药制剂与抗菌药物联合治疗组与抗菌药物治疗组相比,治愈率相对危险度(relative risk,RR)为0.78,95%可信区间(confidence interval,CI)为0.71,0.85];安全性RR为2.08,CI为0.96,4.49];加用口服中药制剂治愈率RR为0.75,CI为0.64,0.88];加用中药注射剂的治愈率RR为0.79,CI为0.71,0.88];加用痰热清注射剂的治愈率RR为0.82,CI为0.73,0.92];加用非清热解毒类中药注射剂的治愈率RR为0.74,CI为0.60,0.92];。结论:现有资料表明以中、西医结合治疗医院获得性肺炎可提高其疗效。

Evaluation on Effect of TCM intervention in Hospital-acquired Pneumonia Controlled Trials

Objective： To evaluate the efficacy and safety of TCM intervention hospital-acquired pneumonia. Methods： The method is that collection of TCM intervention treatment of hospital-acquired pneumonia in randomized controlled trials literature, literature layering of different treatment strategies including using the Jadad scoring table to evaluate the quality of the included studies and the evaluation of the trials included in the operating system. Results： In- clusion criteria of eight papers, involving 557 cases patients and meta-analysis results showed that： traditional Chinese medicine preparation and antibacterial drug combination treatment group compared with the antimicrobial treatment group, the cure rate to relative risk （relative risk, RR） is 0.78, 95% confidence interval （confidence interval, CI） is0.71, 0.85]; safety（RR） is to 2.08, C1 is 0.96,4.49]; oral medicine formulations cure rate plus （RR） is to 0.75, CI is 0.64, 0.88]; plus TCM injections cure rate（RR） is to 0.79, CI is 0.71,0.88]; the injections plus Tam＇eqing cure rate（RR） is to 0.82, CI is 0.73,0.92]; Qingrejiedu class plus TCM injections curerate（RR） is 0.74 and CI is 0.60,0.92]. Conclusion： Available information indicates that Western medicine combined with the treatment of hospital-acquired pneumonia may improve its efficacy.